← Product Code [MIX](/submissions/EN/subpart-d%E2%80%94prosthetic-devices/MIX) · K081815 # VOCALIS GEL (K081815) _Cytophil, Inc. · MIX · Jan 5, 2009 · Ear, Nose, Throat · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/EN/subpart-d%E2%80%94prosthetic-devices/MIX/K081815 ## Device Facts - **Applicant:** Cytophil, Inc. - **Product Code:** [MIX](/submissions/EN/subpart-d%E2%80%94prosthetic-devices/MIX.md) - **Decision Date:** Jan 5, 2009 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 874.3620 - **Device Class:** Class 2 - **Review Panel:** Ear, Nose, Throat - **Attributes:** Therapeutic ## Intended Use Vocalis Gel is indicated for vocal fold medialization and vocal fold insufficiency that may be improved by injection of a soft tissue bulking agent. Vocalis Gel injection augments the size of the displaced or deformed vocal fold so that it may meet the opposing fold at the midline for improved phonation. Vocal fold insufficiency associated with serious aspiration difficulties may be an urgent indication. The product is intended to be durable for a minimum of one month. ## Device Story Vocalis Gel is a sterile, latex-free, non-pyrogenic, isotonic, clear gel injectable implant; composed of sterile water, glycerin, mannitol, and carbomer (USP). Device functions as a soft tissue bulking agent for vocal fold medialization; injected into displaced or deformed vocal folds to augment size and facilitate midline closure against the opposing fold. Used in clinical settings by physicians during injection laryngoplasty procedures; guided by nasopharyngoscopy. Provides durable augmentation for at least one month; allows for tissue infiltration over time. Benefits patients by improving phonation and addressing aspiration difficulties associated with vocal fold insufficiency. ## Clinical Evidence Bench testing only. Preclinical safety studies and animal implant studies conducted to evaluate biocompatibility, including irritation, sensitization, cytotoxicity, acute/sub-chronic toxicity, genotoxicity, and hemolysis. Results indicate the device is non-irritant and non-toxic. ## Technological Characteristics Injectable gel implant; components: sterile water (USP), glycerin (USP), mannitol (USP), carbomer (USP). High yield strength, cohesive, shear-thinning for fine-needle injection. Sterilized via steam (computer-controlled autoclave, overkill methodology to 100 SAL). ## Regulatory Identification Ear, nose, and throat synthetic polymer material is a device material that is intended to be implanted for use as a space-occupying substance in the reconstructive surgery of the head and neck. The device is used, for example, in augmentation rhinoplasty and in tissue defect closures in the esophagus. The device is shaped and formed by the suregon to conform to the patient's needs. This generic type of device is made of material such as polyamide mesh or foil and porous polyethylene. ## Predicate Devices - VF Gel ([K080956](/device/K080956.md)) - Coaptite Laryngeal Augmentation System ([K013243](/device/K013243.md)) - Radiesse Laryngeal Implant ([K070090](/device/K070090.md)) - VF Long Term ([K071663](/device/K071663.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K081815 # JAN - 5 2009 # SECTION 4 # 510(k) Summary of Safety and Effectiveness Vocalis Gel Trade Name: Common Name: Vocal Cord Medialization System, Vocal Cord Medialization Classification Name: Official Contact Name: Greg Johnson President & CEO Cytophil, Inc. Address: 5546 N Santa Monica Blvd Whitefish Bay, WI 53217 Phone: 414-961-7372 414-961-6167 Fax: 6/28/2008 #### 4.1 Intended Use Date Prepared: E-mail: Vocalis Gel is indicated for vocal fold medialization and vocal fold insufficiency that may be improved by injection of a soft tissue bulking agent. Vocalis Gel injection augments the size of the displaced or deformed vocal fold so that it may meet the opposing fold at the midline for improved Vocal fold insufficiency associated with serious aspiration phonation. difficulties may be an urgent indication. The product is intended to be durable for a minimum of one month. gjohnson@cytophil.com #### 4.2 Product Description Sterile, latex free, non-pyrogenic, high yield strength, isotonic, clear gel injectable implant. The gel consists primarily of sterile water for injection (USP), glycerin (USP) and mannitol (USP). The high yield strength is created by small amounts of carbomer (USP). The gel carrier allows tissue infiltration over time. All components are listed as GRAS (Generally Recognized as Safe 21 CFR 182). The character of the gel allows it to be very thick and cohesive but sheer to be easily injected through very fine needles with minimal force. Cytophil, Inc. Section 4 4-1 {1}------------------------------------------------ # 4.3 Substantial Equivalence The following is the predicate device that is substantially equivalent to Vocalis Gel: #### K080956 Modification to VF Gel Coapt Systems, Inc. 1820 Embarcadero Rd. Palo Alto, CA 94303 ## K013243 Coaptite Laryngeal Augmentation System BioForm Medical, Inc. 4133 Courtney Road, Suite 10 Franksville, WI 53126 #### K070090 Radiesse Laryngeal Implant BioForm Medical, Inc. 1875 South Grant St., Suite 110 San Mateo, CA 94402 K071663 VF Long Term Coapt Systems, Inc. 1820 Embarcadero Rd. Palo Alto, CA 94303 ### 4.4 Biocompatibility Evaluations The battery of preclinical safety studies and animal implant studies show that Vocalis Gel is biocompatible when injected into soft tissues. #### 4.5 Sterilization Vocalis Gel is sterilized using steam. Processing is preformed by a contract sterilization company, Haemonetics, using a computer controlled autoclave system. Cycle parameters were validated using an overkill methodology to 100 SAL. Sterilization by the user is not required. Cytophil, Inc. Section 4 4-2 {2}------------------------------------------------ # 4.6 Pre-Clinical Tests Performed In vivo and in vitro tests were performed to address irritation, sensitization, cytotoxicity, acute and sub-chronic toxicity, genotoxicity and hemolysis. Results identified Vocalis Gel as a nonirritant, and nontoxic with no concerns for long-term safety. ## 4.7 Risk Assessment ਼ ਸ The primary risks with Vocalis Gel have been identified through a risk assessment procedure in accordance with EN 1441. The risks identified are primarily associated with nasopharyngoscopy and injection laryngoplasty. #### 4.8 Summary Vocalis Gel is a safe and effective implant used as a space filling material for soft tissue augmentation in laryngeal procedures for vocal fold medialization and augmentation. Section 4 4-3 {3}------------------------------------------------ ## DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular seal with the department's name around the perimeter. Inside the circle is an emblem featuring an abstract image of an eagle. #### Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Cytophil, Inc. c/o Mr. Greg Johnson President & CEO 5546 N Santa Monica Blvd Whitefish Bay, WI 53217 AN - 5 2009 Re: K081815 Trade/Device Name: Vocalis Gel Regulation Number: 21 CFR 874.3620 Regulation Name: Ear, Nose, and Throat Synthetic Polymer Material Regulatory Class: Class II Product Code: MIX Dated: December 12, 2008 Received: December 15, 2008 Dear Mr. Johnson: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {4}------------------------------------------------ Page 2 -- Mr. Greg Johnson This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Malina B. Egleston, and Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ K0818/5 # SECTION 2 # Indications for Use # 510(k) Number: K081815 Device Name: Vocalis Gel Indications for Use: Vocalis Gel is indicated for vocal fold medialization and vocal fold insufficiency that may be improved by injection of a soft tissue bulking agent. Vocalis Gel injection augments the size of the displaced or deformed vocal fold so that it may meet the opposing fold at the midline for improved phonation. Vocal fold insufficiency associated with serious aspiration difficulties may be an urgent indication. The product is intended to be durable for a minimum of one month. (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use or Over-the-Counter Use X (Per 21 CFR 801.109 Daniel Cearron (Division Sign-Off) Division of Ophthalmic and Ear, Nose and Throat Devices 510(k) Number K081815 Section 2 --- **Source:** [https://fda.innolitics.com/submissions/EN/subpart-d%E2%80%94prosthetic-devices/MIX/K081815](https://fda.innolitics.com/submissions/EN/subpart-d%E2%80%94prosthetic-devices/MIX/K081815) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com